Bioventus BVS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.54M+179% | $27.27M+158% | $9.35M+117% | -$501K+99.1% | -$43.99M-59.6% | ||
| $46.35M-6.6% | $47.01M-5.1% | $47.72M-3.8% | $48.59M-5.0% | $49.64M-5.8% | ||
| $13.52M+6.5% | $12.67M-4.5% | $11.25M-13.7% | $10.56M-14.6% | $12.7M+228% | ||
| -$817K— | -$909K— | —— | —— | —— | ||
| $0+100% | -$81K+72.3% | -$373K+68.8% | -$374K+85.6% | -$373K+89.6% | ||
| $836K— | $1.26M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$7.8M-155% | -$8.57M-152% | $9.96M— | $12.77M— | $14.25M— | ||
| —— | —— | —— | —— | —— | ||
| $1.06M-59.6% | $1.16M-58.7% | $2.26M+21.0% | $2.61M+70.8% | $2.61M+26.5% | ||
| $102.94M+304% | $74.67M+92.5% | $56.03M+87.7% | $36.25M— | $25.47M— | ||
| $2.31M+49.9% | $2.56M+155% | $2.56M+219% | $2.15M-22.6% | $1.54M-62.4% | ||
| -$3M-113% | -$3.25M-114% | $21.44M— | $21.85M— | $23.14M— | ||
| $40M+100% | $45M+200% | $35M— | $25M+257% | $20M-31.0% | ||
| $2.04M-15.4% | $2.07M-15.1% | $2.67M+78.1% | $3.12M+133% | $2.42M+177% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $19.77M+11,810% | $9M+24,900% | ||
| —— | $697K-40.9% | $817.75K-54.6% | $938.5K-61.2% | $1.06M-65.2% | ||
| -$86.23M-73.3% | -$62.14M-13.1% | -$76.55M-533% | -$56.57M— | -$49.75M— | ||
| —— | —— | —— | —— | —— | ||
| $13.04M— | $9.66M— | —— | —— | —— | ||
| $96K-89.1% | $392K+51.4% | $491K— | $1.16M— | $878K— | ||
| $0+100% | -$81K+72.3% | -$373K+68.8% | -$374K+85.6% | -$373K+89.6% | ||
| $836K— | $1.26M— | —— | —— | —— | ||
| —— | -$686K-103% | $5.66M-79.2% | $12M-59.6% | $18.34M-43.0% | ||
| —— | $65.77M— | $49.32M— | $32.88M— | $16.44M— | ||
| —— | $0-100% | $1.13M-66.7% | $2.25M0.0% | $3.38M+200% | ||
| -$844K-8.5% | -$827K-9.1% | -$813K-10.5% | -$797K-11.8% | -$778K-19.1% | ||
| $40M+100% | $45M+200% | $35M— | $25M+257% | $20M-31.0% | ||
| $634K— | $240K— | —— | —— | —— | ||
| —— | —— | —— | $19.77M— | $9M— | ||
| —— | —— | —— | —— | $15M— | ||
| $100.63M+321% | $72.11M+90.8% | $53.47M+84.1% | $34.1M+304% | $23.93M+768% | ||
| $100.63M+321% | $72.11M+90.8% | $53.47M+84.1% | $34.1M+304% | $23.93M+768% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bioventus generate?
- Bioventus (BVS) generated $102.9M in operating cash flow over the trailing twelve months.
- What is Bioventus's free cash flow?
- After $2.3M of capital expenditures, Bioventus's free cash flow was $100.6M over the trailing twelve months, up 320.5% year over year.
- Where does Bioventus's cash flow data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
